Long‐term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high‐risk prostate cancer

To determine long‐term oncological outcomes of radical prostatectomy (RP) after neoadjuvant chemohormonal therapy (CHT) for clinically localised, high‐risk prostate cancer.

[1]  E. Basch.  Toward patient-centered drug development in oncology. , 2013, The New England journal of medicine.

[2]  Charles A Enke,et al.  Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  Deepa Naishadham,et al.  Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.

[4]  B. Ljung,et al.  Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. , 2012, The Journal of the National Comprehensive Cancer Network.

[5]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[6]  L. Fazli,et al.  Phase 1/2 study of preoperative docetaxel and mitoxantrone for high‐risk prostate cancer , 2010, Cancer.

[7]  W. Lowrance,et al.  Long‐term follow‐up of 3‐month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial , 2010, BJU international.

[8]  E. Gallardo,et al.  Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer , 2009, British Journal of Cancer.

[9]  L. Schwartz,et al.  NCCN clinical practice guidelines in oncology: testicular cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  M. Gleave,et al.  Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. , 2008, The Journal of urology.

[11]  E. Sacco,et al.  Long‐term follow‐up of a neoadjuvant chemohormonal taxane‐based phase II trial before radical prostatectomy in patients with non‐metastatic high‐risk prostate cancer , 2007, BJU international.

[12]  P. Scardino,et al.  Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.

[13]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[14]  A. Zisman,et al.  NEOADJUVANT CHEMOHORMONAL THERAPY IN POOR-PROGNOSIS LOCALISED PROSTATE CANCER , 2006 .

[15]  P. Scardino,et al.  Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? , 2006, Cancer.

[16]  M. Gleave,et al.  High-risk localized prostate cancer: a case for early chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Walsh.  Docetaxel and Estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer , 2005 .

[18]  P. Kantoff,et al.  Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. , 2004, The Journal of urology.

[19]  J. Eastham,et al.  Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. , 2003, Urology.

[20]  J. Chin,et al.  Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. , 2003, The Journal of urology.

[21]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[22]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[23]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[24]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[25]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[26]  A. Zisman,et al.  Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. , 2008, Urology.

[27]  D. Wood,et al.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.

[28]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[29]  J. Hugosson,et al.  The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. , 1996, European urology.

[30]  D. Wood,et al.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. , 1995, The Journal of urology.

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.